Ovarian cancer cells are fuel-hungry, consuming glucose, amino acids, and fatty acids at rates far exceeding normal cells. The idea of “starving” the cancer means cutting off these fuel sources, and researchers are pursuing this from multiple angles: drugs that block blood vessel growth, therapies that target metabolic pathways, and dietary strategies that may make tumors more vulnerable to treatment. Some of these approaches are already part of standard care, while others are still in clinical trials.
Why Cancer Cells Are Vulnerable to Starvation
Ovarian cancer cells reprogram their metabolism to support rapid growth. The most well-known change is called the Warburg effect: cancer cells burn through glucose at an abnormally high rate, even when oxygen is plentiful. Normal cells would switch to a more efficient energy pathway, but cancer cells stick with this fast, wasteful form of glucose processing. This heavy glucose dependence is one reason tumors light up on PET scans.
But glucose isn’t the only fuel. When glucose runs low, ovarian cancer cells can pivot to glutamine, an amino acid, converting it to energy faster than normal cells can. Glutamine feeds directly into the cell’s central energy cycle and supplies raw materials for building new cells. In lab studies, depriving ovarian cancer cells of glutamine slowed their growth, triggered cell death, and stalled the cell cycle. This metabolic flexibility is what makes ovarian cancer hard to starve through any single approach.
How Ovarian Cancer Feeds on Fat
One of the more striking discoveries about ovarian cancer is its relationship with body fat. When ovarian cancer spreads, it frequently lands on the omentum, a fatty tissue apron that hangs over the intestines. This isn’t random. Fat cells in the omentum actively feed tumor cells by providing fatty acids, and co-culturing human omental fat cells with ovarian cancer cells in the lab promoted tumor growth, migration, and invasion.
At the boundary between fat cells and tumor cells, researchers have identified a protein called FABP4 that shuttles fatty acids into the cancer. Another enzyme, SIK2, is upregulated in fat-rich tumor deposits and helps cancer cells burn those fatty acids for energy. This fat-fueled metabolism directly promotes the spread of ovarian cancer to new sites. Blocking these pathways is an active area of drug development. In preclinical studies, antibodies against the fat-uptake receptor CD36 showed anti-tumor and anti-metastatic effects, and a small molecule inhibitor called BMS309403 significantly reduced fat accumulation in ovarian cancer cells and slowed omental spread.
Cutting Off the Blood Supply
The most established way to “starve” ovarian cancer in clinical practice is to block the growth of new blood vessels that feed the tumor. Bevacizumab, a drug that targets the protein tumors use to recruit blood vessels, is already part of standard ovarian cancer treatment. Without an adequate blood supply, tumors lose access to oxygen and nutrients.
The survival data supports this approach. In recurrent ovarian cancer, patients who received bevacizumab in their second-line treatment had a median progression-free survival of 9.7 months, compared to just 3.0 months for those who did not receive it. Skipping bevacizumab independently predicted worse outcomes, with more than three times the risk of disease progression. This benefit held regardless of whether the cancer was platinum-sensitive or platinum-resistant.
Amino Acid Deprivation Therapy
Some ovarian cancer subtypes lack the ability to make their own arginine, an amino acid essential for cell growth. This creates a potential vulnerability: if you deplete arginine from the bloodstream, normal cells (which can make their own) survive, while arginine-dependent cancer cells starve. A drug called ADI-PEG20 does exactly this. It breaks down arginine in the blood and is currently in Phase 1 through 3 trials for various cancers.
No clinical trials of ADI-PEG20 have been completed specifically in ovarian cancer yet. The main reason is that the most common subtype, high-grade serous carcinoma, tends to produce its own arginine. However, rarer ovarian cancer subtypes, including small cell carcinoma of the ovary (hypercalcemic type), do lack this ability and responded to arginine depletion in preclinical studies. Researchers have called for a gynecological cancer-focused trial as a next step.
Metformin and Metabolic Disruption
Metformin, the widely used diabetes drug, has drawn attention for its potential to disrupt cancer cell metabolism. It activates an energy-sensing enzyme in cells that, among other effects, suppresses a key growth-signaling pathway (mTOR) that ovarian cancer cells rely on. It also lowers circulating insulin levels, which indirectly reduces signals that promote cancer cell growth. In lab studies, metformin triggered cell cycle arrest in ovarian cancer cells and improved their sensitivity to chemotherapy.
The clinical evidence, however, is mixed. A few studies have suggested better outcomes for ovarian cancer patients who were already taking metformin for diabetes, but the numbers were small, ranging from 12 to 61 women. More recent, larger registry-based studies have not confirmed a clear survival benefit. Metformin remains an area of interest, but it’s not currently recommended as a cancer treatment outside of clinical trials.
Fasting-Mimicking Diets During Treatment
Short-term fasting or fasting-mimicking diets (FMDs) represent a different angle on the starvation concept. Rather than permanently eliminating a nutrient, these diets involve brief periods of very low calorie intake, typically around the time of chemotherapy. The idea is rooted in a biological principle called differential stress resistance: when nutrients drop sharply, normal cells shift into a protective, low-energy mode, while cancer cells, unable to stop growing, become more vulnerable.
In animal studies combining FMDs with chemotherapy for ovarian cancer, researchers observed large reductions in tumor cell size, decreased cell proliferation, and increased cancer cell death. Similar benefits appeared across breast cancer, leukemia, and melanoma models. The FMD also appeared to reduce chemotherapy’s side effects on healthy tissue, creating what researchers describe as a dual benefit: less toxicity for the patient and greater damage to the tumor.
These results are promising but come primarily from animal models. The specific protocols (how long to fast, how few calories to consume, which chemotherapy cycles to pair it with) are still being refined in human studies. Attempting prolonged fasting without medical guidance carries real risks, particularly for cancer patients who may already be losing weight or muscle mass.
What Diet Changes Can and Cannot Do
The search for ways to starve cancer often leads people to wonder whether simply cutting sugar from their diet will help. The biology is more complicated than that. While ovarian cancer cells do consume glucose at high rates, your body tightly regulates blood sugar levels. Even on a zero-sugar diet, your liver produces glucose from protein and fat to maintain blood sugar. You cannot selectively starve a tumor of glucose through diet alone.
That said, the general dietary guidance from the National Cancer Institute aligns with metabolic common sense: limit added sugars, saturated fat, sodium, and alcohol. These recommendations are designed to reduce cancer risk and support health during treatment, not to directly starve tumors. Maintaining adequate protein and calorie intake is critical during cancer treatment, since muscle wasting is a serious complication that worsens outcomes and quality of life.
The most realistic path to “starving” ovarian cancer combines targeted medical therapies (like bevacizumab and metabolic drugs in trials) with evidence-informed dietary strategies that support your body’s ability to tolerate treatment. The metabolic vulnerabilities of ovarian cancer are real and increasingly well understood, and they’re being translated into treatments, but they work through precise biochemical targeting rather than through food restriction alone.